Universal PropTech Inc. Announces Agreement with LuminUltra Technologies to Provide SARS-CoV-2 (COVID-19) Surface Testing
UPI" or the "
Company") is pleased to announce that is has entered into an agreement on February 5, 2021 with LuminUltra Technologies Ltd. ("
LuminUltra") to deploy their GeneCount Rapid SARS-CoV-2 surface testing solution for UPI's current and past customers which total over 2,000 facilities including certain aviation assets in Canada today. The Agreement provides UPI the ability to provide testing services employing LuminUltra's GeneCount® qPCR tests as a service.
Chris Hazelton, President and CEO of UPI commented: "
We are very excited to bring LuminUltra's
highly reputable SARS-CoV-2 surface testing solution to our customer base in Canada to ensure workplaces are sanitary and safe," Mr. Hazelton continued: